Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Deferoxamine for Patients with Aneurysmal Subarachnoid Hemorrhage

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called Deferoxamine in patients who have experienced an aneurysmal subarachnoid hemorrhage. An aneurysmal subarachnoid hemorrhage is a type of bleeding that occurs in the space around the brain, often due to a burst blood vessel. The purpose of the study is to investigate how Deferoxamine, which is administered as a solution for injection or infusion, can impact the recovery process in these patients.

Participants in the study will receive either Deferoxamine or a placebo. The study will monitor the presence of new ischemia, which is a condition where blood flow (and thus oxygen) is restricted or reduced in a part of the body, at two weeks and six months after treatment. Additionally, the study will assess various outcomes related to neurological and functional health, such as serum ferritin levels and scores on scales like the modified Rankin Scale (mRS), the Glasgow Outcome Scale-Extended (GOS-E), and the EQ-5D, which is a standardized measure of health status.

The trial will follow participants over a period of time to gather data on these outcomes, aiming to provide insights into the potential benefits of Deferoxamine for individuals who have suffered from an aneurysmal subarachnoid hemorrhage. This research could help improve understanding and treatment of this serious condition.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment

    Eligibility is confirmed based on criteria such as age (18-85 years), diagnosis of subarachnoid hemorrhage by CT, and successful surgical or endovascular treatment.

    Written informed consent is obtained from the patient.

  2. Step 2

    Initial assessment

    Initial health assessments are conducted to establish baseline measurements.

    These assessments include neurological and functional evaluations using scales like mRS, GOS-E, and EQ-5D.

  3. Step 3

    Treatment administration

    The medication deferoxamine mesilate is administered intravenously.

    The dosage and frequency are determined by the study protocol and medical team.

  4. Step 4

    Monitoring and follow-up

    Regular monitoring is conducted to observe the effects of the treatment.

    Control imaging is performed at 2 weeks and 6 months to check for new ischemia.

    Serum ferritin levels and other health indicators are measured.

  5. Step 5

    Final assessment

    A comprehensive evaluation is conducted at the end of the study period.

    This includes a review of neurological and functional outcomes using the same scales as the initial assessment.

Who can join the trial?

8 criteria

  • Age between 18 and 85 years old.
  • Diagnosed with a subarachnoid hemorrhage by a CT scan when admitted to the hospital. A subarachnoid hemorrhage is bleeding in the space around the brain.
  • No history of the subarachnoid hemorrhage being caused by an injury.
  • Can be included in the study within 72 hours of the subarachnoid hemorrhage occurring.
  • Has a saccular intracranial aneurysm confirmed by cerebral angiography or CTA. This means there is a bulge in a blood vessel in the brain.
  • Has had successful surgical or endovascular treatment to fix the aneurysm. Endovascular treatment is a procedure done inside the blood vessels.
  • Able to provide written informed consent, meaning the patient understands the study and agrees to participate.
  • In good clinical condition, with a WFNS score of 1-3 and a GCS score of 13-15 at the time of randomization. WFNS and GCS are scales used to assess the severity of brain injury and the patient's level of consciousness.

Who cannot join the trial?

3 criteria

  • Patients who have a medical condition other than a subarachnoid hemorrhage, which is bleeding in the space around the brain.
  • Patients who are not within the specified age range for the study.
  • Patients who belong to a vulnerable population, meaning they might need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Deferoxamine is a medication being studied for its potential benefits in patients who have experienced an aneurysmal subarachnoid hemorrhage, which is a type of bleeding in the brain. The study aims to see if using deferoxamine can help reduce the risk of new ischemic events, which are areas of reduced blood flow in the brain, as observed in follow-up imaging. Additionally, the study will assess the impact of deferoxamine on various health and recovery scales over a six-month period.

What is already known about the treatment

Deferoxamine – Deferoxamine is administered intravenously and is being studied for its potential use in treating aneurysmal subarachnoid hemorrhage. It is currently under investigation in clinical trials, with a focus on its ability to reduce new ischemic events in patients. The main therapeutic indication being explored is its use in managing complications following subarachnoid hemorrhage. At the molecular level, deferoxamine works by binding to excess iron in the body, which may help prevent oxidative damage to brain tissues. It is classified as an iron-chelating agent, traditionally used to treat iron overload conditions.

Investigated diseases

Subarachnoid Hemorrhage – This condition occurs when there is bleeding in the space between the brain and the surrounding membrane, known as the subarachnoid space. It often results from a ruptured aneurysm, which is a weakened area in a blood vessel. The bleeding can lead to increased pressure on the brain, causing severe headaches, neck stiffness, and sensitivity to light. As the condition progresses, it may result in confusion, decreased consciousness, or even coma. The bleeding can also cause complications such as vasospasm, where blood vessels constrict, potentially leading to reduced blood flow and ischemia. Recovery and symptoms can vary widely depending on the severity and location of the hemorrhage.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2024-514615-10-01Estimated enrolment40 patientsSponsorStichting Radboud universitair medisch centrum

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).